帕金森病患者皮质与皮质下微结构与临床进展及体液生物标志物的关联
本研究基于帕金森进展标志物倡议的纵向数据(2011年4月至2022年7月),纳入174例有基线扩散MRI和至少2年临床随访的帕金森病患者,分析皮质与皮质下平均弥散率(MD)与临床评分年变化率及体液生物标志物的关联。线性混合效应模型显示,MD值(主要位于皮质下区、颞叶、枕叶和额叶)与临床评分年变化率显著相关;MD还与基线血清神经丝轻链及脑脊液α-突触核蛋白、β-淀粉样蛋白1-42、磷酸化tau181和苏总tau水平相关,提示微结构特性可能有助于分层快速临床进展患者。
要点
- 基线皮质与皮质下MD值主要位于皮质下区、颞叶、枕叶和额叶,与临床评分年变化率显著相关。
- MD与基线血清神经丝轻链及脑脊液α-突触核蛋白、β-淀粉样蛋白1-42、磷酸化tau181和苏总tau水平相关。
- MD衍生的β系数与健康志愿者脑中多巴胺、谷氨酸、5-羟色胺、大麻素和γ-氨基丁酸A受体神经递质受体/转运体的空间分布一致。
核心结论
- 基线皮质与皮质下MD值与临床进展及基线体液生物标志物相关,提示微结构特性可能有助于分层快速临床进展的帕金森病患者。
研究设计与样本
- 本研究为纵向研究,使用帕金森进展标志物倡议的数据,收集时间为2011年4月至2022年7月。
- 共纳入174例有基线扩散MRI和至少2年临床随访的帕金森病患者,年龄61.9±9.7岁,63%为男性。
- 临床评估采用运动障碍学会赞助修订的统一帕金森病评定量表(UPDRS)和蒙特利尔认知评估(MoCA)评分,临床评估随访至5年。
- 采用线性混合效应模型检验MD与临床评分年变化率的关联,采用偏相关分析检验MD与体液生物标志物水平的关联。
主要发现
- 线性混合效应模型显示,MD值(主要位于皮质下区、颞叶、枕叶和额叶)与临床评分年变化率显著相关:UPDRS第一部分标准化β>2.35;UPDRS第二部分标准化β>2.34;姿势不稳和步态障碍评分标准化β>2.47;MoCA标准化β<-2.42;所有p<0.05,FDR校正。
- MD与基线血清神经丝轻链水平相关(r>0.22),与基线脑脊液α-突触核蛋白(右侧壳核r=0.31)、β-淀粉样蛋白1-42(左侧海马r=-0.30)、磷酸化tau181(r>0.26)和苏总tau(r>0.23)水平相关;所有p<0.05,FDR校正。
- 从MD和临床评分年变化率衍生的β系数与健康志愿者脑中PET扫描显示的多巴胺(DAT、D1和D2)、谷氨酸(mGluR5和NMDA)、5-羟色胺(5-HT1a和5-HT2a)、大麻素(CB1)和γ-氨基丁酸A受体神经递质受体/转运体的空间分布一致(p<0.05,FDR校正)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Mean diffusivity (MD) of diffusion MRI (dMRI) has been used to measure cortical and subcortical microstructural properties. This study investigated relationships of cortical and subcortical MD, clinical progression, and fluid biomarkers in Parkinson disease (PD). METHODS: This longitudinal study using data from the Parkinson's Progression Markers Initiative was collected from April 2011 to July 2022. Clinical symptoms were assessed with Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS) and Montreal Cognitive Assessment (MoCA) scores. Clinical assessments were followed up to 5 years. Linear mixed-effects (LME) models were performed to examine associations of MD and the annual rate of changes in clinical scores. Partial correlation analysis was conducted to examine the associations of MD and fluid biomarker levels. RESULTS: A total of 174 patients with PD (age 61.9 ± 9.7 years, 63% male) with baseline dMRI and at least 2 years of clinical follow-up were included. Results of LME models revealed a significant association between MD values, predominantly in subcortical regions, temporal lobe, occipital lobe, and frontal lobe, and annual rate of changes in clinical scores (UPDRS-Part-I, standardized β > 2.35; UPDRS-Part-II, standardized β > 2.34; postural instability and gait disorder score, standardized β > 2.47; MoCA, standardized β < -2.42; all p < 0.05, false discovery rate [FDR] corrected). In addition, MD was associated with the levels of neurofilament light chain in serum (r > 0.22) and α-synuclein (right putamen r = 0.31), β-amyloid 1-42 (left hippocampus r = -0.30), phosphorylated tau at 181 threonine position (r > 0.26), and total tau (r > 0.23) in CSF at baseline (all p < 0.05, FDR corrected). Furthermore, the β coefficients derived from MD and annual rate of changes in the clinical score recapitulated the spatial distribution of dopamine (DAT, D1, and D2), glutamate (mGluR5 and NMDA), serotonin (5-HT1a and 5-HT2a), cannabinoid (CB1), and γ-amino butyric acid A receptor neurotransmitter receptors/transporters (p < 0.05, FDR corrected) derived from PET scans in the brain of healthy volunteers. DISCUSSION: In this cohort study, cortical and subcortical MD values at baseline were associated with clinical progression and baseline fluid biomarkers, suggesting that microstructural properties could be useful for stratification of patients with fast clinical progression.
引用
- Wang L, Zhou C, Zhang W, et al. Association of Cortical and Subcortical Microstructure With Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease. Neurology. 2023. PMID: 37202161. doi:10.1212/WNL.0000000000207408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。